BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划

路透中文

Oct 15, 2025

BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划

10月15日 - ** 药物开发商Keros Therapeutics KROS.O股价早盘上涨1.8%，至15.36美元

** 公司将以每股17.75美元的价格回购ADAR1 Capital Management和Pontifax Venture Capital持有的全部股份，总价1.81亿美元

** 公司计划以每股17.75美元的价格回购最多1.94亿美元的股票

** 将在 2028 年底前向股东返还武田制药许可收益的 25% - KROS

** Keros Therapeutics董事会成员Ran Nussbaum和Tomer Kariv在交易后辞职 - KROS

** 公司称回购是 3.75 亿美元资本回报计划的一部分；资金来自现金储备

** 针对肌肉萎缩性疾病 DMD 的 KER-065 中期试验将于 2026 年第一季度开始 - KROS

** 截至上一交易日收盘，股价累计下跌 ~5

(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2575787740"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575787740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575787740?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-10-15 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575787740","market":"us","top_or_hot":-1,"title":"BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划</title></head><body><p><span>10月15日</span><span> - </span>** 药物开发商Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KROS.O</span>股价早盘上涨1.8%，至15.36美元</p><p>** 公司将以每股17.75美元的价格回购ADAR1 Capital Management和Pontifax Venture Capital持有的全部股份，总价1.81亿美元</p><p>** 公司计划以每股17.75美元的价格回购最多1.94亿美元的股票 </p><p>** 将在 2028 年底前向股东返还<a href=\"https://laohu8.com/S/TAK\">武田制药</a>许可收益的 25% - KROS</p><p>** Keros Therapeutics董事会成员Ran Nussbaum和Tomer Kariv在交易后辞职 - KROS</p><p>** 公司称回购是 3.75 亿美元资本回报计划的一部分；资金来自现金储备 </p><p>** 针对肌肉萎缩性疾病 DMD 的 KER-065 中期试验将于 2026 年第一季度开始 - KROS</p><p>** 截至上一交易日收盘，股价累计下跌 ~5</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time\">2025-10-15 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划</title></head><body><p><span>10月15日</span><span> - </span>** 药物开发商Keros <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>KROS.O</span>股价早盘上涨1.8%，至15.36美元</p><p>** 公司将以每股17.75美元的价格回购ADAR1 Capital Management和Pontifax Venture Capital持有的全部股份，总价1.81亿美元</p><p>** 公司计划以每股17.75美元的价格回购最多1.94亿美元的股票 </p><p>** 将在 2028 年底前向股东返还<a href=\"https://laohu8.com/S/TAK\">武田制药</a>许可收益的 25% - KROS</p><p>** Keros Therapeutics董事会成员Ran Nussbaum和Tomer Kariv在交易后辞职 - KROS</p><p>** 公司称回购是 3.75 亿美元资本回报计划的一部分；资金来自现金储备 </p><p>** 针对肌肉萎缩性疾病 DMD 的 KER-065 中期试验将于 2026 年第一季度开始 - KROS</p><p>** 截至上一交易日收盘，股价累计下跌 ~5</p><p>(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KROS","symbol_name":"Keros Therapeutics, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251015:nL3T3VW10R:1","article_id":"2575787740","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575787740","pubTimestamp":1760533444,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KROS":"Keros Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"BUZZ-Keros rises after premium acquisition of stake in major investor; Launches $194 million buyback program","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KROS":0.9},"content_text":"BUZZ-Keros 溢价收购主要投资者股份后股价上涨；推出 1.94 亿美元回购计划10月15日 - ** 药物开发商Keros Therapeutics KROS.O股价早盘上涨1.8%，至15.36美元** 公司将以每股17.75美元的价格回购ADAR1 Capital Management和Pontifax Venture Capital持有的全部股份，总价1.81亿美元** 公司计划以每股17.75美元的价格回购最多1.94亿美元的股票 ** 将在 2028 年底前向股东返还武田制药许可收益的 25% - KROS** Keros Therapeutics董事会成员Ran Nussbaum和Tomer Kariv在交易后辞职 - KROS** 公司称回购是 3.75 亿美元资本回报计划的一部分；资金来自现金储备 ** 针对肌肉萎缩性疾病 DMD 的 KER-065 中期试验将于 2026 年第一季度开始 - KROS** 截至上一交易日收盘，股价累计下跌 ~5(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,buyback,merge","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}